TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - NOVO-NORDISK B TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - NOVO-NORDISK B Share Price
Certificat
DE000CJ60FK4
| Market Closed - Börse Stuttgart 12:28:04 31/05/2024 pm IST | ||
| 20.3 EUR | -1.36% |
|
| Current month | +4.80% | ||
| 1 month | +4.80% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 31/24/31 | 20.3 | -1.36% |
| 30/24/30 | 20.58 | +2.49% |
| 29/24/29 | 20.08 | -1.71% |
| 28/24/28 | 20.43 | -0.83% |
| 27/24/27 | 20.6 | +0.19% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 12:28 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | CJ60FK |
| ISIN | DE000CJ60FK4 |
| Date issued | 03/01/2019 |
| Strike | 165 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.16 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 20.6 € |
|---|---|
| Lowest since issue | 0.058 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Certificates
- Certificat
